Takano Y
Nihon Jinzo Gakkai Shi. 1989 Nov;31(11):1187-96.
78 patients with essential hypertension (17 with borderline hypertension and 61 with hypertension) and 13 normal controls were examined to evaluate the relation between the urinary excretion rate of guanidinoacetic acid/creatinine (U-GAA/Cr), beta 2-microglobulin/creatinine (U-BMG/Cr), radio-sensitive microalbumin excretion rate/creatinine (U-AER/Cr), N-acetyl-D-glucosaminidase/creatinine (U-NAG/Cr) and renal function. There was no significant difference among these groups in creatinine clearance (Ccr), serum creatinine (Cr) or in U-BMG/Cr, U-NAG/Cr and U-AER/Cr. In hypertensive patients U-GAA/Cr was 49.2 +/- 16.7 mg/gCr, which was much lower than in controls (78.1 +/- 13.4) (p less than 0.001). The Ccr has a significant relation with U-GAA/Cr (r = 0.29, p less than 0.01) but not with U-AER/Cr, U-BMG/Cr nor U-NAG/Cr. In 44 patients, all of the above factors were investigated for 24 weeks during 4 kinds of anti-hypertensive treatment (10 with an angiotensin-converting enzyme inhibitor: A group, 11 with a beta-adrenergic blocker: B group, 12 with a Ca entry blocker: C group and 12 with diuretics: D group). In A and C group, U-GAA/Cr was elevated during therapeutic course. However, in B and D group it declined during treatment. These findings suggested that urinary excretion of GAA may be a more sensitive marker than AER, BMG or NAG in hypertension and angiotensin-converting enzyme inhibitor and Ca entry blocker can be useful in the treatment of patients with essential hypertension with renal damage.
对78例原发性高血压患者(17例临界高血压患者和61例高血压患者)及13名正常对照者进行检查,以评估胍基乙酸/肌酐尿排泄率(U-GAA/Cr)、β2-微球蛋白/肌酐(U-BMG/Cr)、放射免疫法测定的微量白蛋白排泄率/肌酐(U-AER/Cr)、N-乙酰-D-氨基葡萄糖苷酶/肌酐(U-NAG/Cr)与肾功能之间的关系。这些组间的肌酐清除率(Ccr)、血清肌酐(Cr)以及U-BMG/Cr、U-NAG/Cr和U-AER/Cr无显著差异。高血压患者的U-GAA/Cr为49.2±16.7mg/gCr,显著低于对照组(78.1±13.4)(p<0.001)。Ccr与U-GAA/Cr显著相关(r = 0.29,p<0.01),但与U-AER/Cr、U-BMG/Cr和U-NAG/Cr无关。对44例患者在4种抗高血压治疗(10例使用血管紧张素转换酶抑制剂:A组,11例使用β-肾上腺素能阻滞剂:B组,12例使用钙通道阻滞剂:C组,12例使用利尿剂:D组)期间进行了24周的上述所有因素调查。在A组和C组,治疗过程中U-GAA/Cr升高。然而,在B组和D组,治疗期间其下降。这些结果表明,在高血压中,胍基乙酸的尿排泄可能是比微量白蛋白排泄率、β2-微球蛋白或N-乙酰-D-氨基葡萄糖苷酶更敏感的标志物,血管紧张素转换酶抑制剂和钙通道阻滞剂可用于治疗有肾损害的原发性高血压患者。